These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 16247965)
21. The inhibitory efficacy of RNA POL III-expressed long hairpin RNAs targeted to untranslated regions of the HIV-1 5' long terminal repeat. Barichievy S; Saayman S; von Eije KJ; Morris KV; Arbuthnot P; Weinberg MS Oligonucleotides; 2007; 17(4):419-31. PubMed ID: 17896874 [TBL] [Abstract][Full Text] [Related]
23. HIV-1 inactivation by nucleic acid aptamers. Held DM; Kissel JD; Patterson JT; Nickens DG; Burke DH Front Biosci; 2006 Jan; 11():89-112. PubMed ID: 16146716 [TBL] [Abstract][Full Text] [Related]
24. Promoter choice affects the potency of HIV-1 specific RNA interference. Boden D; Pusch O; Lee F; Tucker L; Shank PR; Ramratnam B Nucleic Acids Res; 2003 Sep; 31(17):5033-8. PubMed ID: 12930953 [TBL] [Abstract][Full Text] [Related]
25. A lentiviral vector that activates latent human immunodeficiency virus-1 proviruses by the overexpression of tat and that kills the infected cells. Macías D; Oya R; Saniger L; Martín F; Luque F Hum Gene Ther; 2009 Nov; 20(11):1259-68. PubMed ID: 19604078 [TBL] [Abstract][Full Text] [Related]
26. Towards developing HIV-2 lentivirus-based retroviral vectors for gene therapy: dual gene expression in the context of HIV-2 LTR and Tat. Sadaie MR; Zamani M; Whang S; Sistron N; Arya SK J Med Virol; 1998 Feb; 54(2):118-28. PubMed ID: 9496370 [TBL] [Abstract][Full Text] [Related]
27. Sequence and structure requirements for specific recognition of HIV-1 TAR and DIS RNA by the HIV-1 Vif protein. Freisz S; Mezher J; Hafirassou L; Wolff P; Nominé Y; Romier C; Dumas P; Ennifar E RNA Biol; 2012 Jul; 9(7):966-77. PubMed ID: 22767258 [TBL] [Abstract][Full Text] [Related]
28. Tat functions to stimulate the elongation properties of transcription complexes paused by the duplicated TAR RNA element of human immunodeficiency virus 2. García-Martínez LF; Mavankal G; Peters P; Wu-Baer F; Gaynor RB J Mol Biol; 1995 Dec; 254(3):350-63. PubMed ID: 7490754 [TBL] [Abstract][Full Text] [Related]
29. Cooperative and specific binding of Vif to the 5' region of HIV-1 genomic RNA. Henriet S; Richer D; Bernacchi S; Decroly E; Vigne R; Ehresmann B; Ehresmann C; Paillart JC; Marquet R J Mol Biol; 2005 Nov; 354(1):55-72. PubMed ID: 16236319 [TBL] [Abstract][Full Text] [Related]
30. Inhibition of human immunodeficiency virus type-1 by retroviral vectors expressing antisense-TAR. Chuah MK; VandenDriessche T; Chang HK; Ensoli B; Morgan RA Hum Gene Ther; 1994 Dec; 5(12):1467-75. PubMed ID: 7711139 [TBL] [Abstract][Full Text] [Related]
31. A simple assay system for examination of the inhibitory potential in vivo of decoy RNAs, ribozymes and other drugs by measuring the Tat-mediated transcription of a fusion gene composed of the long terminal repeat of HIV-1 and a gene for luciferase. Koseki S; Ohkawa J; Yamamoto R; Takebe Y; Taira K J Control Release; 1998 Apr; 53(1-3):159-73. PubMed ID: 9741924 [TBL] [Abstract][Full Text] [Related]
32. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Stopak K; de Noronha C; Yonemoto W; Greene WC Mol Cell; 2003 Sep; 12(3):591-601. PubMed ID: 14527406 [TBL] [Abstract][Full Text] [Related]
33. Incorporation of aptamers in the terminal loop of shRNAs yields an effective and novel combinatorial targeting strategy. Pang KM; Castanotto D; Li H; Scherer L; Rossi JJ Nucleic Acids Res; 2018 Jan; 46(1):e6. PubMed ID: 29077949 [TBL] [Abstract][Full Text] [Related]
34. Block of Tat-mediated transactivation of tumor necrosis factor beta gene expression by polymeric-TAR decoys. Brother MB; Chang HK; Lisziewicz J; Su D; Murty LC; Ensoli B Virology; 1996 Aug; 222(1):252-6. PubMed ID: 8806505 [TBL] [Abstract][Full Text] [Related]
35. Aromatic polyamidines inhibiting the Tat-induced HIV-1 transcription recognize structured TAR-RNA. Mischiati C; Jeang KT; Feriotto G; Breda L; Borgatti M; Bianchi N; Gambari R Antisense Nucleic Acid Drug Dev; 2001 Aug; 11(4):209-17. PubMed ID: 11572598 [TBL] [Abstract][Full Text] [Related]
36. RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy. Li M; Li H; Rossi JJ Ann N Y Acad Sci; 2006 Oct; 1082():172-9. PubMed ID: 17145937 [TBL] [Abstract][Full Text] [Related]
37. Lentivirus-mediated RNA interference therapy for human immunodeficiency virus type 1 infection. Morris KV; Rossi JJ Hum Gene Ther; 2006 May; 17(5):479-86. PubMed ID: 16716105 [TBL] [Abstract][Full Text] [Related]
38. Naf1 Regulates HIV-1 Latency by Suppressing Viral Promoter-Driven Gene Expression in Primary CD4+ T Cells. Li C; Wang HB; Kuang WD; Ren XX; Song ST; Zhu HZ; Li Q; Xu LR; Guo HJ; Wu L; Wang JH J Virol; 2017 Jan; 91(1):. PubMed ID: 27795436 [TBL] [Abstract][Full Text] [Related]
39. Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCR5 shRNA, and a TAR decoy. Anderson JS; Javien J; Nolta JA; Bauer G Mol Ther; 2009 Dec; 17(12):2103-14. PubMed ID: 19690520 [TBL] [Abstract][Full Text] [Related]
40. Mathematical model of the Tat-Rev regulation of HIV-1 replication in an activated cell predicts the existence of oscillatory dynamics in the synthesis of viral components. Likhoshvai VA; Khlebodarova TM; Bazhan SI; Gainova IA; Chereshnev VA; Bocharov GA BMC Genomics; 2014; 15 Suppl 12(Suppl 12):S1. PubMed ID: 25564443 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]